.png "Tetraphase (NASDAQ: TTPH)")
In a report released yesterday, Madhu Kumar from Robert W. Baird maintained a Buy rating on Tetraphase (TTPH), with a price target of $3. The company’s shares closed yesterday at $1.60, close to its 52-week low of $1.01.
According to TipRanks.com, Kumar is a 4-star analyst with an average return of 8.2% and a 38.5% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Clementia Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tetraphase with a $6.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.64 and a one-year low of $1.01. Currently, Tetraphase has an average volume of 700K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.
